Skip to main content

View full-text article in PMC

. 2012 Nov 17;3(11):1455–1471. doi: 10.18632/oncotarget.696

Table 1. Relative hazard of recurrence free survival in univariate and multivariate analysis.

		Univariate			Multivariate
		HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
miR-30d^−high SOCS1^−low	30d < 7.95, SOCS1 ≥ 8.20 (n = 42)
miR-30d^−high SOCS1^−low	30d ≥ 7.95, SOCS1 < 8.20 (n = 14)	3.404	1.312-8.831	0.012				4.447	1.614-12.254	0.004
miR-30d^-high	< 7.95 (n = 28)
miR-30d^-high	≥ 7.95 (n = 28)	2.963	1.052-8.342	0.04	5.926	1.748-20.094	0.003
SOCS1^−low	< 8.20 (n = 28)
SOCS1^−low	≥ 8.20 (n = 28)	2.026	0.779-5.269	0.148	1.940	0.717-5.248	0.192
Tumor stage	pT 2 (n = 32)
Tumor stage	pT 3 (n = 24)	2.266	0.873-5.880	0.093	3.512	1.087-11.350	0.036	2.618	0.892-7.685	0.08
Gleason score	≤ 6 (n = 14)
	7 (n = 26)	0.437	0.145-1.314	0.141	0.352	0.098-1.266	0.110	0.464	0.145-1.484	0.195
	≥ 8 (n = 16)	0.598	0.181-1.977	0.4	0.401	0.095-1.703	0.216	0.643	0.167-2.473	0.520
Age (years)	< 68 (n = 24)
Age (years)	≥ 68 (n = 32)	0.595	0.211-1.673	0.325	0.642	0.211-1.954	0.435	0.685	0.222-2.119	0.512
Pre-operative PSA (ng/ml)	> 10.6 (n = 28)
Pre-operative PSA (ng/ml)		≥ 10.6 (n = 28)	1.614	0.625-4.167	0.323	1.638	0.533-5.030	0.389	1.610	0.574-4.516	0.365

HR, hazard ratio; Cl, confidence interval.